Movement Alert｜Guardant Health Inc. Falls 5.08% in Regular Trading, patent litigation overhang weighs on sentiment ahead of earnings

On November 2, Guardant Health Inc. fell 5.08% in Regular Trading, trading at $169.9025, with turnover of $55.722 million.

The clearest catalyst was continued pressure from a patent litigation setback tied to duplex sequencing, which has weighed on sentiment ahead of the company’s upcoming earnings report on November 5.

Recent developments show the company’s challenge to 30 claims of a U.S. patent was rejected, leaving intact an earlier finding of willful infringement. The ruling preserved more than $245.2 million in damages, accrued royalties, and interest through May, and the company was also ordered to pay a 6% royalty on implicated products and services from June until the patent expires. That legal overhang has offset otherwise constructive expectations around Shield commercialization, test coverage expansion, and prior favorable analyst views on Guardant Health Inc.’s growth in tumor profiling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)